# Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

> **NCT07437287** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 160 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** mFOLFOX regimen
- **DRUG:** Mitazalimab

## Key facts

- **NCT ID:** NCT07437287
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-04
- **Final completion:** 2031-10
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07437287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07437287, "Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07437287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*